Climb Bio, Inc. reports initial Phase 1b data show robust B cell depletion in ITP trial

Traders Union
All News
Companies
Climb Bio reports early ITP data

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Market Voices

Companies

Ivan Andriyenko

11.06.2026

Climb Bio, Inc. reports initial Phase 1b data show robust B cell depletion in ITP trial — Climb Bio reports early ITP data

Climb Bio, Inc. has announced initial results from its Phase 1b clinical trial, revealing that Budoprutug achieved on-target clinical activity in immune thrombocytopenia (ITP).

The data, presented at the EHA Hematology meeting, show Budoprutug delivered robust B cell depletion, a favorable safety and tolerability profile, and encouraging early platelet responses in treated patients. These findings support Budoprutug's potential for further clinical development in the treatment of ITP.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Climb Bio previously reported initial safety and platelet data from its Phase 1b/2a Budoprutug trial in ITP at the EHA congress, highlighting early results from the study (see article). The company also discussed its broader immunology strategy and plans for autoimmune research during a Jefferies fireside chat (see article). Both updates outline Climb Bio’s ongoing clinical and research activities in the autoimmune space.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Proof of Reserves: the new standard for cryptocurrency exchanges

By Pavlo Kot
4 hours ago

Proof of Reserves: the new standard for cryptocurrency exchanges

Editors' Picks

Three trends that could reshape the crypto market over the next decade

By Eugene Komchuk
Yesterday

Three trends that could reshape the crypto market over the next decade

Editors' Picks

Trump financial disclosure: How the president's crypto income became a U.S. ethics issue

By Oleg Tkachenko
02.07.2026

Trump financial disclosure: How the president's crypto income became a U.S. ethics issue

Editors' Picks

All Editors' Top Picks

Latest Climb Bio News

Climb Bio, Inc. targets late summer readout for initial Phase 1 CLYM116 data in healthy volunteers

By Elena Nikulina
Yesterday

Climb Bio, Inc. targets late summer readout for initial Phase 1 CLYM116 data in healthy volunteers

Companies

Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study

By Ashutosh Sureka
01.07.2026

Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study

Companies

Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach

By Mikhail Vnuchkov
29.06.2026

Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach

Companies

All Climb Bio News

Pavlo Kot
4 hours ago

Proof of Reserves: the new standard for cryptocurrency exchanges

Eugene Komchuk
Yesterday

Three trends that could reshape the crypto market over the next decade

Oleg Tkachenko
02.07.2026

Trump financial disclosure: How the president's crypto income became a U.S. ethics issue

Pavlo Kot
01.07.2026

Code red: What's behind Bitcoin’s sharp selloff?

Anastasiia Chabaniuk
01.07.2026

MiCA is live: How EU new rules are changing crypto market

Yaroslav Dmytrenko
13 min ago

Bitget offers U.S. stock options and crypto in one platform, Kevin Susanto notes

Hlib Chabaniuk
28 min ago

Shay Boloor: Nebius secures 18MW lease as it expands into Spain

Jose Antonio Gastelum
28 min ago

Sky Wee: TGE events should be seen as infrastructure launches

Daria Chernytska
43 min ago

BTC++ Toronto event generates excitement among speakers, Peter Todd notes

Andrey Mastykin
48 min ago

Millions of children to get investment accounts from birth, Brad Gerstner notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Pavlo Kot
4 hours ago

Proof of Reserves: the new standard for cryptocurrency exchanges

Proof of Reserves: the new standard for cryptocurrency exchanges

Parshwa Turakhiya
Yesterday

Bitcoin pushes toward $62,000 as risk appetite returns

Bitcoin pushes toward $62,000 as risk appetite returns

Ivan Andriyenko
Yesterday

EU-U.S. trade boom leaves German carmakers behind

EU-U.S. trade boom leaves German carmakers behind

Eugene Komchuk
Yesterday

Christine Lagarde may leave ECB earlier than expected

Christine Lagarde may leave ECB earlier than expected

Jose Antonio Gastelum
Yesterday

Brazil sets tougher standards for crypto service providers

Brazil sets tougher standards for crypto service providers

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft rebounds as AI confidence improves after sharp correction

Anton Kharitonov
Now

Alphabet extends recovery as AI optimism offsets macro uncertainty

Mykhailo Ihnatenko
Now

Defense spending pushes Rolls-Royce shares toward record highs

Anton Kharitonov
Now

Bitcoin rebounds as softer U.S. jobs data lifts risk appetite

Anton Kharitonov
Now

WTI stays under pressure as weak U.S. jobs data adds demand risk

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.